Clinical Trial Update: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) [Phase 1]

View source ↗

Summary

This update reports termination of the first-in-human Phase 1 trial of the VOB560-MIK665 combination in relapsed/refractory hematologic malignancies (Non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• MIK665
• VOB560

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML) | Phase 1 | Status: TERMINATED